HSK7653
Type 2 Diabetes
Phase IIIActive
Key Facts
About Haisco Pharmaceutical Group
Haisco Pharmaceutical Group's mission is to develop and deliver innovative, high-quality medicines to address unmet medical needs in China and globally. The company has achieved significant scale, becoming one of China's top pharmaceutical firms by market value, through a successful 'generic-to-innovative' transition strategy. Its core strategy is built on vertical integration, using stable cash flows from its generics and established drug portfolio to fund R&D in high-growth therapeutic areas, while expanding its commercial reach across China's vast healthcare market.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |